Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AIN457 Regimen Finding Extension Study in Patients With Moderate to Severe Psoriasis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 19, 2010
Last updated: December 18, 2013
Last verified: December 2013

The purpose of this study is to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

Condition Intervention Phase
Plaque-type Psoriasis
Drug: AIN457
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety and tolerability as measured by the number of patients with Adverse Events and clinically significant changes in vital signs and clinical laboratory variables. [ Time Frame: 81 +157 (prolongation) weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Long-term efficacy as assessed by the number of patients with a PASI 50, PASI 75 and PASI 90 achievement and an improvement of the Investigator' global assessment score during the trial. [ Time Frame: 81 +157 (prolongation) weeks ] [ Designated as safety issue: No ]
  • To evaluate the long-term immunogenicity by measuring the number of patients developing anti AIN antibodies during the trial. [ Time Frame: 81 +157 (prolongation) weeks ] [ Designated as safety issue: No ]

Enrollment: 275
Study Start Date: April 2010
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fixed-time interval regimen
Fixed-time interval regimen
Drug: AIN457
Experimental: Treatment at start of relapse regimen
Treatment at start of relapse regimen
Drug: AIN457
Experimental: Open-label
Drug: AIN457
Placebo Comparator: Placebo
Drug: Placebo


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who completed the core study CAIN457A2211. A patient is defined as having completed the core study if he/she completed the study up to and including visit 13 (F4) of the core study
  • Patients must be able to understand and communicate with the investigator and comply with the requirement of the study and must given written, signed and dated informed consent before any study assessment is performed.
  • Patients must be expected to benefit from the ongoing treatment with AIN457, as assessed by the patient and investigator
  • Male patients must consent to practice reliable contraception during the study and for 16 weeks after the last dose of study drug administration

Exclusion Criteria:

  • Patients who experience a second consecutive full relapse at visit 13 ( week F4) of the core study CAIN457A2211
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until termination of gestation, confirmed by a positive hCG laboratory test (> 5mlU/mL)
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are:

    • women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
    • women whose partners have been sterilized by vasectomy or other means
    • using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, condoms (by the partner) and some intrauterine devices (IUDs); Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) are not acceptable

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01132612

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham, Dept of Dermatology
Birmingham, Alabama, United States, 35233
United States, Arkansas
Clinical Study Centers
Little Rock, Arkansas, United States, 72205
United States, California
Therapeutics Clinical Research
San Diego, California, United States, 92123
Huntington Medical Foundation
San Marino, California, United States, 91108
United States, Georgia
Medaphase Inc
Newnan, Georgia, United States, 30263
Gwinnett Clinical Research Center
Snellville, Georgia, United States, 30078
United States, Illinois
Christie Clinic
Champaign, Illinois, United States, 61820
Springfield Clinic
Springfield, Illinois, United States, 62703
United States, Indiana
Deaconess Clinic
Evansville, Indiana, United States, 47713
United States, Kansas
Cotton-O'Neil Clinical Research Center
Topeka, Kansas, United States, 66606
United States, Kentucky
Physician Skin Care
Louisville, Kentucky, United States, 40217
United States, Michigan
Michigan Center for Research Corp. DBA Michigan Center for Skin Care Research
Clinton Twp, Michigan, United States, 48038
HFMC-New Center One, Department of Dermatology
Detroit, Michigan, United States, 48202
United States, Minnesota
University of Minnisota-Dept of Dermatology
Minneapolis, Minnesota, United States, 55454
United States, Missouri
Central Dermatology
St. Louis, Missouri, United States, 63117
United States, Nebraska
Creighton University - Dept. of Dermatology
Omaha, Nebraska, United States, 68131
Skin Specialist, PC
Omaha, Nebraska, United States, 68144
United States, Nevada
Dermatology Consulting Services
Henderson, Nevada, United States, 89052
United States, New York
Skin Search of Rochester, Inc
Rochester, New York, United States, 14623
United States, North Carolina
Dermatology Consulting Services
High Point, North Carolina, United States, 27262
United States, Oregon
Allergy, Asthma & Dermatology Research Center, LLC
Lake Oswego, Oregon, United States, 97035
Oregon Dermatology and Research Center
Portland, Oregon, United States, 97210
United States, Texas
DermResearch, Inc
Austin, Texas, United States, 78759
Baylor Research Institute - Dermatology
Dallas, Texas, United States, 75246
United States, Virginia
Charlottesville Medical Research
Charlottesville, Virginia, United States, 22911
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative site
Bonn, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative site
Goettingen, Germany
Novartis Investigative site
Hamburg, Germany
Novartis Investigative site
Hannover, Germany
Novartis Investigative site
Kiel, Germany
Novartis Investigative site
Mainz, Germany
Novartis Investigative site
Muenster, Germany
Novartis Investigative site
Tuebingen, Germany
Novartis Investigative Site
Kopavogur, Iceland
Novartis Investigative site
Afula, Israel
Novartis Investigative site
Petach-Tikva, Israel
Novartis Investigative site
Tel-Hashomer, Israel
Novartis Investigative site
Aichi, Japan
Novartis Investigative site
Fukuoka, Japan
Novartis Investigative site
Gunma, Japan
Novartis Investigative site
Hokkaido, Japan
Novartis Investigative site
Tokyo, Japan
Novartis Investigative site
Bergen, Norway
Novartis Investigative site
Oslo, Norway
Novartis Investigative site
Ålesund, Norway
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT01132612     History of Changes
Other Study ID Numbers: CAIN457A2211E1, 2009-017234-51
Study First Received: May 19, 2010
Last Updated: December 18, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Iceland: Icelandic Medicines Control Agency
Israel: Ministry of Health
Japan: Ministry of Health, Labor and Welfare
Norway: Norwegian Medicines Agency
United States: Food and Drug Administration

Keywords provided by Novartis:
Chronic plaque-type psoriasis
Moderate to severe chronic plaque-type psoriasis

Additional relevant MeSH terms:
Skin Diseases
Skin Diseases, Papulosquamous processed this record on November 24, 2014